Following on from information provided to NICE by the company in May 2018, the appraisal of Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 839 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | Gilead Sciences (idelalisib) |
| Others | Department of Health |
| NHS England | |
| Welsh Government | |
| Patient carer groups | Leukaemia CARE |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Accord Healthcare (fludarabine) (not participating, confidentiality agreement not signed) |
| Actavis (fludarabine) (not participating, confidentiality agreement not signed) | |
| Allergan (fludarabine) (not participating, confidentiality agreement not signed) | |
| Aspen Pharma (chlorambucil) (not participating, confidentiality agreement not signed) | |
| Baxter Healthcare (cyclophosphamide) (not participating, confidentiality agreement not signed) | |
| Genzyme (fludarabine) (not participating, confidentiality agreement not signed) | |
| GlaxoSmithKline (chlorambucil,) (not participating, confidentiality agreement not signed) | |
| Hospira UK (fludarabine) (not participating, confidentiality agreement not signed) | |
| Janssen (ibrutinib) | |
| Pfizer (cyclophosphamide) | |
| Roche Products (rituximab) (not participating, confidentiality agreement not signed) | |
| Sandoz (cyclophosphamide) (not participating, confidentiality agreement not signed) | |
| Sanofi (fludarabine) (not participating, confidentiality agreement not signed) | |
| Teva UK (fludarabine) (not participating, confidentiality agreement not signed) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 31 October 2022 | Following on from information provided to NICE by the company in May 2018, the appraisal of Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 31 October 2022 | Discontinued. Following on from information provided to NICE by the company in May 2018, the appraisal of Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 10 May 2018 | The company have now advised that have withdrawn their marketing authorisation application from the European Medicines Authority (EMA) for this indication at this time. Therefore, this appraisal will remain suspended. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties if the situation changes. For more information, please see the EMA website: http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2018/02/WC500244301.pdf |
| 03 May 2017 | Suspended. This appraisal has formally started now, in line with the anticipated regulatory timelines. However, the Gilead has informed us that they will not provide an evidence submission for this appraisal. NICE will therefore suspend this appraisal with immediate effect. |
| 03 May 2017 | Invitation to participate |
| 08 June 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual